✦ LIBER ✦

PND1 Estimating Net Health Benefits Of Intramuscular Interferon Beta-1A And Fingolimod In Treating Patients With Relapsing-Remitting Multiple Sclerosis

✍ Scribed by S.M. Szabo; C. Dembek; P. Moore; L.A. White; H. Wijaya; A.R. Levy

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gender effects on intramuscular interfer

✍ Rudick, R.; Kappos, L.; Kinkel, R.; Clanet, M.; Phillips, J.; Herndon, R.; Sandr 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 229 KB

Comparison of fingolimod with interferon

✍ Bhupendra Khatri; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Ludwig K 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 228 KB

PND8 COST-EFFECTIVENESS AND BUDGET IMPAC

✍ O Espallardo; C Crespo; C Polanco; D Nieves 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

PND1 A Risk-Benefit Analysis of Natalizu

✍ A.R. Walker; B. Deniz; S.T. Alexopoulos; R. Arnold; D. Bates 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Cost-Effectiveness of Early Initiation o

✍ Neetu Agashivala; Edward Kim 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 316 KB

Matrix metalloproteinase-9 (MMP-9) and t

✍ Cavit Boz; Mehmet Ozmenoglu; Sibel Velioglu; Kagan Kilinc; Asim Orem; Zekeriya A 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 101 KB